Epidemiological Characteristics, Clinical Outcomes and Management Patterns of Metastatic Breast Cancer Patients in Routine Clinical Care Settings of Greece: Results from the EMERGE Multicenter Retrospective Chart Review Study

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2019 Jan 20

PMID 30658600

Citations 5

Authors

Athanasios Kotsakis

Alexandros Ardavanis

Georgios Koumakis

Epameinondas Samantas

Amanta Psyrri

Christos Papadimitriou

Affiliations

Soon will be listed here.

Abstract

Background: The "EMERGE" study, aimed to capture real-life management patterns and outcomes in metastatic breast cancer (MBC) in Greece, also accounting for hormone (HR) and human epidermal growth factor receptor 2 (HER2) status.

Methods: "EMERGE" was a multicenter, retrospective cohort study of adult MBC patients diagnosed between 01-Janaury-2010 and 30-June-2012, either de novo or having progressed from a non-metastatic state. Patient data, including treatment patterns and outcomes, were mainly abstracted through medical chart review.

Results: 386 patients were enrolled by 16 hospital-based oncologists between 12-March-2013 and 31-March-2015. The median look-back period was 29.1 months. At MBC diagnosis, 56.1% of the patients were HR/HER2, 16.6% HR/HER2, 14.5% HR/HER2, and 12.8% HR/HER2. In the first line setting, chemotherapy, targeted therapy and endocrine therapy were received by 76.7, 52.4, and 28.3% of the overall population, and by 66.5/36.2/42.0%, 80.4/80.4/28.6%, 88.4/90.7/0.0, and 95.6%/56.5/6.5% of the HR/HER2, HR/HER2, HR/HER2, HR/HER2 subpopulations, respectively. In the overall population, the disease progression incidence rate was 0.57 [95% confidence interval (CI): 0.48-0.67] per person-year; median progression-free survival (PFS) was 22.4 (95% CI: 20.4-24.7) and overall survival (OS) was 45.0 (95% CI: 40.9-55.0) months. Median PFS was 24.6 (95% CI: 21.3-27.9) in HR/HER2, 19.7 (95% CI: 12.9-25.9) in HR/HER2, 23.0 (95% CI: 16.6-29.7) in HR/HER2 and 18.3 (95% CI: 10.0-24.7) months in HR/HER2 subpopulations. A multivariable Cox proportional hazards model, adjusted among other factors for age and duration of diagnosis, HR and HER2 status, demonstrated that in the overall population PFS was better among those receiving first line endocrine therapy (hazard ratio: 0.70; 95%CI: 0.51-0.95; p = 0.024).

Conclusions: "EMERGE" demonstrates differences between HR/HER2 subtypes in clinical outcomes and divergence from evidence-based guideline recommendations for MBC management, especially as it pertains to the HR/HER2 patients in which chemotherapy was favored over endocrine therapy in the first line setting.

Study Registration: The study has been registered on the electronic Registry of Non-Interventional Studies (RNIS) posted on the website of the Hellenic Association of Pharmaceutical Companies (SFEE): https://www.dilon.sfee.gr/studiesp_d.php?meleti_id=NIS-OGR-XXX-2012/1.

Citing Articles

Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.

Courtinard C, Gourgou S, Jacot W, Carton M, Guerin O, Vacher L BMC Med. 2023; 21(1):87.

PMID: 36882736 PMC: 9993797. DOI: 10.1186/s12916-023-02754-5.

Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis.

Ding C, Shrestha R, Zhu X, Geller A, Wu S, Woeste M Nat Immunol. 2023; 24(2):239-254.

PMID: 36604547 PMC: 10636755. DOI: 10.1038/s41590-022-01388-8.

Ancient mitochondrial diversity reveals population homogeneity in Neolithic Greece and identifies population dynamics along the Danubian expansion axis.

Silva N, Kreutzer S, Souleles A, Triantaphyllou S, Kotsakis K, Urem-Kotsou D Sci Rep. 2022; 12(1):13474.

PMID: 35931723 PMC: 9356035. DOI: 10.1038/s41598-022-16745-8.

Effect of Psychological Intervention-Assisted Comfort Nursing Based on PERMA Model on Stress and Psychological Changes of Patients after Breast Cancer Surgery.

Chen B, Luo T, Cai Q, Pan F, Liang D, Hu Y Comput Math Methods Med. 2022; 2022:1853754.

PMID: 35712008 PMC: 9197632. DOI: 10.1155/2022/1853754.

Thidiazuron decreases epithelial-mesenchymal transition activity through the NF-kB and PI3K/AKT signalling pathways in breast cancer.

Rajendran P, Ammar R, Al-Saeedi F, Mohamed M, Islam M, Al-Ramadan S J Cell Mol Med. 2020; 24(24):14525-14538.

PMID: 33159487 PMC: 7754050. DOI: 10.1111/jcmm.16079.

References

Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D . Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat. 2005; 97(3):237-44. DOI: 10.1007/s10549-005-9117-4. View

Pentheroudakis G, Fountzilas G, Kalofonos H, Golfinopoulos V, Aravantinos G, Bafaloukos D . Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol. 2008; 66(3):237-47. DOI: 10.1016/j.critrevonc.2007.12.003. View

Lu J, Steeg P, Price J, Krishnamurthy S, Mani S, Reuben J . Breast cancer metastasis: challenges and opportunities. Cancer Res. 2009; 69(12):4951-3. DOI: 10.1158/0008-5472.CAN-09-0099. View

Dafni U, Grimani I, Xyrafas A, Eleftheraki A, Fountzilas G . Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat. 2009; 119(3):621-31. DOI: 10.1007/s10549-009-0630-8. View

Dawood S, Broglio K, Ensor J, Hortobagyi G, Giordano S . Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol. 2010; 21(11):2169-2174. PMC: 2962259. DOI: 10.1093/annonc/mdq220. View

Kiely B, Soon Y, Tattersall M, Stockler M . How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol. 2010; 29(4):456-63. DOI: 10.1200/JCO.2010.30.2174. View

Cheng Y, Ueno N . Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer. 2011; 19(3):191-9. PMC: 3860359. DOI: 10.1007/s12282-011-0276-3. View

Geiger S, Cnossen J, Horster S, DiGioia D, Heinemann V, Stemmler H . Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005. Anticancer Drugs. 2011; 22(9):933-9. DOI: 10.1097/CAD.0b013e32834860af. View

Colombo P, Milanezi F, Weigelt B, Reis-Filho J . Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res. 2011; 13(3):212. PMC: 3218943. DOI: 10.1186/bcr2890. View

10.

Berman A, Thukral A, Hwang W, Solin L, Vapiwala N . Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clin Breast Cancer. 2012; 13(2):88-94. DOI: 10.1016/j.clbc.2012.11.001. View

11.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

12.

Giuliano M, Trivedi M, Schiff R . Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. Breast Care (Basel). 2014; 8(4):256-62. PMC: 3808214. DOI: 10.1159/000354253. View

13.

Swallow E, Zhang J, Thomason D, Tan R, Kageleiry A, Signorovitch J . Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. Curr Med Res Opin. 2014; 30(8):1537-45. DOI: 10.1185/03007995.2014.908829. View

14.

Howlader N, Altekruse S, Li C, Chen V, Clarke C, Ries L . US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014; 106(5). PMC: 4580552. DOI: 10.1093/jnci/dju055. View

15.

Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S . Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist. 2014; 19(6):608-15. PMC: 4041678. DOI: 10.1634/theoncologist.2014-0002. View

16.

Lee H, Park I, Park S, Seo A, Lim B, Chai Y . Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. Breast Cancer Res Treat. 2014; 145(3):615-23. DOI: 10.1007/s10549-014-2983-x. View

17.

Parise C, Caggiano V . Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. J Cancer Epidemiol. 2014; 2014:469251. PMC: 4058253. DOI: 10.1155/2014/469251. View

18.

Lobbezoo D, van Kampen R, Voogd A, Dercksen M, van den Berkmortel F, Smilde T . Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?. Br J Cancer. 2015; 112(9):1445-51. PMC: 4453676. DOI: 10.1038/bjc.2015.127. View

19.

Lobbezoo D, van Kampen R, Voogd A, Dercksen M, van den Berkmortel F, Smilde T . In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol. 2015; 27(2):256-62. DOI: 10.1093/annonc/mdv544. View

20.

Wang Y, Sun T, Wan D, Sheng L, Li W, Zhu H . Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study. Onco Targets Ther. 2015; 8:3337-48. PMC: 4648606. DOI: 10.2147/OTT.S91166. View